Thermo Fisher Scientific Inc. (NYSE:TMO) closed its highly anticipated $3.6 billion acquisition of Swedish blood test maker Phadia.

The all-cash deal, which is closed yesterday, gives Thermo Fisher expanded reach in specialty diagnostics. Phadia supplies more than 70 percent of the world’s allergy laboratory tests and 40 percent of autoimmunity tests.